

Change in multimodal MRI markers predicts dementia risk in cerebral small vessel disease

OPEN 

Eva A. Zeestraten, PhD
Andrew J. Lawrence, PhD
Christian Lambert, PhD
Philip Benjamin, MD,
PhD
Rebecca L. Brookes, PhD
Andrew D. Mackinnon,
MD
Robin G. Morris, PhD
Thomas R. Barrick, PhD
Hugh S. Markus, MD,
PhD

Correspondence to
Dr. Zeestraten:
p1207006@sgul.ac.uk

ABSTRACT

Objective: To determine whether MRI markers, including diffusion tensor imaging (DTI), can predict cognitive decline and dementia in patients with cerebral small vessel disease (SVD).

Methods: In the prospective St George's Cognition and Neuroimaging in Stroke study, multimodal MRI was performed annually for 3 years and cognitive assessments annually for 5 years in a cohort of 99 patients with SVD, defined as symptomatic lacunar stroke and confluent white matter hyperintensities (WMH). Progression to dementia was determined in all patients. Progression of WMH, brain volume, lacunes, cerebral microbleeds, and a DTI measure (the normalized peak height of the mean diffusivity histogram distribution) as a marker of white matter microstructural damage were determined.

Results: Over 5 years of follow-up, 18 patients (18.2%) progressed to dementia. A significant change in all MRI markers, representing deterioration, was observed. The presence of new lacunes, and rate of increase in white matter microstructural damage on DTI, correlated with both decline in executive function and global functioning. Growth of WMH and deterioration of white matter microstructure on DTI predicted progression to dementia. A model including change in MRI variables together with their baseline values correctly classified progression to dementia with a C statistic of 0.85.

Conclusions: This longitudinal prospective study provides evidence that change in MRI measures including DTI, over time durations during which cognitive change is not detectable, predicts cognitive decline and progression to dementia. It supports the use of MRI measures, including DTI, as useful surrogate biomarkers to monitor disease and assess therapeutic interventions. *Neurology*® 2017;89:1869-1876

GLOSSARY

AUC = area under the receiver operating characteristic curve; **CMB** = cerebral microbleeds; **DSM-5** = *Diagnostic and Statistical Manual of Mental Disorders, 5th edition*; **DTI** = diffusion tensor imaging; **EF** = executive function; **IADL** = Instrumental Activities of Daily Living; **LME** = linear mixed effect; **MD** = mean diffusivity; **MMSE** = Mini-Mental State Examination; **NAWM** = normal-appearing white matter; **NPH** = normalized peak height; **PS** = processing speed; **SCANS** = St George's Cognition and Neuroimaging in Stroke; **SVD** = small vessel disease; **WM** = white matter; **WMH** = white matter hyperintensities.

Cerebral small vessel disease (SVD) is the major pathology underlying vascular dementia and an important cause of age-related cognitive decline.¹ While many elderly patients develop radiologic signs of SVD,² only a minority progress to dementia. Better methods are required to identify the subgroup who rapidly decline.

Using rate of cognitive decline as a predictive tool in SVD has been shown to be limited³ due to the slow rate of decline⁴ and insensitivity of cognitive tests to change. Research has therefore focused on using MRI features of SVD, such as lacunes, white matter hyperintensities (WMH), and brain atrophy,^{5,6} as surrogate markers.⁷ Diffusion tensor imaging (DTI) is of particular

Supplemental data
at Neurology.org

From the Neuroscience Research Centre (E.A.Z., C.L., P.B., T.R.B.), Cardiovascular and Cell Sciences Research Institute, St George's University of London; Stroke Research Group (A.J.L., R.L.B., H.S.M.), Clinical Neurosciences, University of Cambridge; Atkinson Morley Regional Neuroscience Centre (A.D.M.), St George's NHS Healthcare Trust; and Department of Psychology (R.G.M.), King's College Institute of Psychiatry, Psychology, and Neuroscience, London, UK.

Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing charge was funded by Wellcome Trust.

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

interest; it is highly sensitive to white matter (WM) microstructural damage in SVD and demonstrates widespread abnormalities in the apparently normal-appearing WM (NAWM).⁸

Cross-sectional studies have shown that both lacunes and diffuse WM damage detected on DTI are associated with cognitive impairment.^{9–12} It has been hypothesized that both result in white matter track disruption, and disconnection of distributed networks underlying executive function (EF) and processing speed (PS), the 2 domains most affected in SVD.^{13,14} However, almost all previous data are cross-sectional and therefore give information only on association, not prediction. The longitudinal St George's Cognition and Neuroimaging in Stroke (SCANS) study was established to determine whether change in multimodal MRI, including DTI, predicts cognitive decline and dementia in SVD.

METHODS Patients. Details of the SCANS study have been published previously.^{7,10} In brief, patients presenting with symptomatic SVD, defined as a clinical lacunar stroke syndrome¹⁵ with

MRI evidence of an anatomically corresponding lacunar infarct, and with confluent regions of WMH graded ≥ 2 on the modified Fazekas scale,¹⁶ were enrolled from 3 stroke services covering a geographically contiguous region in South London. Patients underwent MRI annually for 3 years and cognitive testing annually for 5 years. At each visit, repeat recordings of cardiovascular risk factors and blood pressure were performed. Data on progression to dementia were collected during follow-up and from hospital and family doctor records.

Standard protocol approvals, registrations, and patient consents. The study was approved by the Wandsworth (London) research ethics committee and all patients provided written informed consent. The study is registered with the UK Clinical Research Network (public.ukcrn.org.uk/; study ID 4577).

Available data. A total of 121 patients were recruited. Of these, 103 attended more than one cognitive assessment. Eighteen patients only attended one assessment due to death (n = 7), study withdrawal (n = 6), house move (n = 1), lost to follow-up (n = 2), or withdrawal from full neuropsychological testing (n = 2). Of the 103 who attended cognitive assessments more than once, MRI data at multiple time points were available for 99; 4 withdrew from imaging but remained in the study for neuropsychological testing. In this analysis, we describe the relationship between change of MRI measures and both cognitive change and progression to dementia in all 99 who had at least one follow-up MRI. The number of complete MRI and cognitive assessments at each time point are shown in table e-1 at Neurology.org.

Demographic characteristics of the 99 patients (table 1) who attended one or more follow-up MRI and cognitive sessions compared to the 22 who did not have been described previously.⁴ There were no significant differences in any imaging measures between the groups, but patients who remained in the study were

Table 1 Baseline and change characteristics of the analyzed cohort

Baseline characteristics	Mean (SD)			
Age, y	68.9 (10.0)			
MMSE	27.9 (2.4)			
Premorbid IQ	99.6 (15.6)			
Rankin	1.1 (1.0)			
Male sex, %	66 (66.7)			
IADL	7.59 (0.93)			
Change characteristics	Mean baseline value (range)	Incident findings		
Lacunes	4.2 (0–27)	74 in 27 patients		
Microbleeds	5.5 (0–144)	173 in 35 patients		
	Estimated mean baseline value (SD)	Estimated mean annual change (SD)	χ^2	p Value
WMH lesion load (log)	0.450 (0.341)	0.082 (0.033)	322.0	<0.001
TCV, mL	1,045.85 (102.2)	–13.84 (3.72)	310.3	<0.001
MD-NPH, mm ² /s	0.0152 (0.0028)	–3.72 × 10 ^{–4} (8.14 × 10 ^{–6})	141.7	<0.001
Executive function	–0.903 (0.966)	–0.048 (0.047)	10.2	0.001
Processing speed	–0.964 (0.787)	–0.052 (0.060)	14.3	<0.001
Working memory	–0.202 (0.780)	0.007 (<0.001)	0.3	0.609
Long-term memory	–0.037 (0.926)	0.022 (0.044)	3.0	0.082
Global functioning	–0.651 (0.721)	–0.029 (0.036)	11.1	<0.001

Abbreviations: IADL = Instrumental Activities of Daily Living; MD-NPH = normalized peak height of mean diffusivity histogram distribution; MMSE = Mini-Mental State Examination; TCV = total cerebral volume; WMH = white matter hyperintensity, in % of total cerebral volume log transformed. Annualized change measures were estimated through linear mixed effect models with a random intercept and slope model fit.

younger and had higher baseline Mini-Mental State Examination (MMSE) scores. At study entry, no patients had had intracerebral hemorrhage, had superficial siderosis, or met the modified Boston criteria for definite, probable, or possible cerebral amyloid angiopathy.¹⁷

MRI acquisition. MRI at baseline and each follow-up visit were acquired using the same 1.5T GE Signa HDxt system (General Electric, Milwaukee, WI) using identical image acquisition protocols as previously published¹⁰ and described in appendix e-1.

MRI analysis. Structural preprocessing. A longitudinal tissue segmentation pipeline optimized to our SVD cohort, described in detail in a previous publication,¹⁸ was performed to obtain segmentations for gray matter, NAWM, WMH, and CSF based on coregistered fluid-attenuated inversion recovery and T1-weighted images.

Conventional MRI markers of SVD. The tissue segmentation maps were used to calculate total cerebral volume and WMH lesion load (log-transformed to adjust for its skewed distribution). Lacunes and cerebral microbleeds (CMB) were identified by a trained independent rater according to agreed neuroimaging standards.^{6,19} Detailed calculations and descriptions for these MRI markers are shown in appendix e-2.

Diffusion preprocessing. Detailed preprocessing steps of diffusion-weighted images have been described elsewhere²⁰ and in appendix e-3. Preprocessing was applied to evaluate the normalized mean diffusivity (MD) histogram distributions of all WM tissue (i.e., NAWM plus WMH) (range 0–0.004 mm²/s, bin width 0.000004 mm²/s). The normalized frequency of voxels with the histogram peak value in all WM tissue, the MD normalized peak height (MD-NPH) (figure e-1), was used as a measure of tissue microstructure over time as we have previously shown it is the most stable and sensitive DTI measure of change.²⁰

Cognitive assessment. Cognitive index scores. A battery of well-established, standardized tasks sensitive to the cognitive impairments seen in SVD was carried out annually. Full details have been published previously.¹⁰ In brief, cognitive tasks (table e-2) were age-scaled using published normative data, converted to *z* scores, and grouped into broad cognitive domains. Averaging across component scores within each cognitive domain created cognitive index scores for EF, PS, working memory, and long-term memory. An overall global functioning score based on all administered tests was produced. In addition, premorbid intelligence was assessed.

Dementia. Information on conversion to dementia was available for all 99 patients. Dementia was diagnosed using the DSM-5²¹ definition of major neurocognitive disorder, and was present if individuals met one of the following criteria:

1. A diagnosis of dementia made in a memory clinic or equivalent clinical service
2. After review of medical records and cognitive assessments by a neurologist and clinical neuropsychologist, both blinded to MRI and risk factor information, who agreed that the clinical picture met DSM-5 criteria
3. An MMSE score consistently <24, indicative of cognitive impairment,²² and reduced capabilities in daily living as measured by a score ≤7 on the Instrumental Activities of Daily Living (IADL)²³

The presence of dementia was determined before comparison of cognitive and MRI data. Date of dementia onset was defined as the date of diagnosis. If no exact date was known and dementia conversion was based on review of patient data or cognitive

performance, the midpoint date between the visit at which the diagnosis was established and the previous visit was used.

Statistical analyses. We employed linear mixed effect (LME) models to estimate annualized change rates in MRI and cognitive markers based on all available time points. MRI and cognitive indices data were modeled separately in MLwiN 2.1 (Centre for Multilevel Modelling, University of Bristol).²⁴ Intercepts and linear trajectories (i.e., annual change rate) across the follow-up period as a function of time were allowed to vary with fixed and random effects. The presence of detectable change was assessed on the basis of significance of the average fixed effect slope of time evaluated using a Wald test. Slopes for each patient as estimated by the LME models were extracted and used for further analyses.

First, univariate linear regression analyses were performed between annualized cognitive change rates and MRI markers using SPSS 22.0 (IBM Corp., Armonk, NY). Lacunes and CMB were treated as binary variables (i.e., no change or any new lesions), due to the low frequency of new lesions. Multivariate stepwise linear regression analysis was used to investigate the relationship between annualized change rates of different MRI markers with cognitive decline. Baseline age, premorbid IQ, and sex were added as covariates.


Predictive abilities of MRI change rates and vascular risk factors for dementia conversion were assessed by univariate Cox regression. LME estimates of change in MRI variables for these dementia models were recalculated to exclude MRI data acquired after conversion to dementia (*n* = 3 participants, *n* = 3 observations). This ensured that only imaging data prior to diagnosis were used to predict dementia conversion. Continuous risk factors, such as blood pressure, were averaged over all time points. Smoking status was defined as smoking during the majority of follow-up, and diabetes as presence at any point during follow-up. A stepwise multivariate Cox regression model including all annualized MRI change rates and risk factors, plus baseline age, premorbid IQ, and sex, was applied to identify independent predictors of dementia.

To assess classification performance of the regression model, we performed discriminant function analyses. First we identified the discriminant value of a conventional risk factor model including age, sex, premorbid IQ, and cardiovascular risk factors. Subsequently we compared significance, sensitivity and specificity, area under the receiver operating characteristic curve (AUC; equivalent to a C statistic),²⁵ and model stability (i.e., through leave-one-out cross-validation) of that model to that of a model that included the significant variables from the multivariate Cox regression and their baseline values (the relationship between baseline MRI measures and cognition is not investigated in this article, but has been previously published for the 121 patients recruited¹⁰).

RESULTS Conversion to dementia. A total of 18 (18.2%) of 99 patients converted to dementia during the 5-year follow-up. Dementia diagnosis was based on clinical diagnosis (*n* = 8), review of medical records (*n* = 3), and meeting dementia thresholds for MMSE and IADL scores (*n* = 7). Mean (SD) time to dementia conversion was 3.31 ± 1.40 years. Deaths and other endpoints during follow-up are shown in appendix e-4.

Change in MRI and cognitive measures. Over the 3-year imaging period, there was an increase in WMH lesion

Figure 1 Estimated annual change rates for cognitive indices



The dot lines show all estimated individual annual progression rates of executive function, processing speed, and global functioning, as modeled using linear mixed effect models over all available time points.

load, worsening of WM tissue microstructure (decreased MD-NPH), and decreased brain volume (table 1). Seventy-four new lacunes were observed in 27 patients. Nineteen developed 1–2 lacunes, and 8 ≥ 3 (maximum 9). A total of 173 new CMB occurred in 35 individuals; 10 developed a single CMB, 14 developed 2–5 CMB, and 11 developed ≥ 6 CMB.

During 5-year cognitive follow-up, there was a statistically significant decline in EF, PS, and global functioning (table 1). No change in working and long-term memory was observed. We therefore limited further analyses to EF, PS, and global

functioning. Cognitive change varied markedly between individual patients, with some showing marked decline and others no decline. Estimated annualized progression rates are shown in figure 1.

Relationship between imaging change and cognition change. Univariate models showed decline in EF was associated with lower baseline premorbid IQ ($\beta = 0.219, p = 0.026$), greater change of MD-NPH ($\beta = 0.275, p = 0.007$), and new lacunes ($\beta = -0.269, p = 0.003$) but not brain volume ($\beta = -0.030, p = 0.773$) or CMB ($\beta = -0.190, p = 0.061$) or WMH ($\beta = 0.077, p = 0.449$). In contrast, no neuroimaging marker, age, IQ, or sex correlated with decline in PS. Decline in global functioning was associated with lower premorbid IQ ($\beta = 0.307, p = 0.002$), greater change in MD-NPH ($\beta = 0.262, p = 0.011$), new lacunes ($\beta = -0.265, p = 0.004$), and new CMB ($\beta = -0.218, p = 0.035$) but not WMH ($\beta = 0.677, p = 0.500$) or brain volume ($\beta = -0.113, p = 0.277$).

Table 2 shows standardized regression coefficients from multivariate models investigating which MRI markers correlated with cognitive decline. New lacunes, decline in MD-NPH, and premorbid IQ were independently associated with decline in EF. The model explained 17.9% of variance in EF change ($F_{3,91} = 6.63, p < 0.001$). Age, premorbid IQ, change in MD-NPH, and new lacunes were all independent correlates of decline in global functioning, with the model explaining 26.6% of variance ($F_{4,88} = 7.98, p < 0.001$).

Imaging predictors of conversion to dementia. Univariate Cox regression analyses revealed only greater MD-NPH change (hazard ratio 0.004; $p = 0.034$) was indicative of conversion to dementia (table 3).

Table 2 Independent predictors of change in cognitive indices

	Multivariate stepwise regression models		
	Executive function	Processing speed	Global functioning
Baseline age, y	—	—	-0.207 (0.032)
Baseline premorbid IQ	0.246 (0.013)	—	0.338 (0.001)
Sex (male)	—	—	—
Annualized change in MRI measures			
WMH lesion load	—	—	—
TCV	—	—	—
MD-NPH	0.230 (0.021)	—	0.200 (0.040)
Incident lacunes	-0.276 (0.007)	—	-0.347 (0.001)
Incident CMB	—	—	—

Abbreviations: CMB = cerebral microbleeds; MD-NPH = normalized peak height of mean diffusivity histogram distribution, in mm^2/s ; TCV = total cerebral volume, in mL; WMH = white matter hyperintensity, in % of total cerebral volume log transformed.

Values shown are standardized regression coefficients β (p value).

On multivariate Cox regression including all MRI measures, as well as age, sex, IQ, and vascular risk factors, only higher premorbid IQ, greater increase in WMH, and greater decrease in MD-NPH independently predicted conversion to dementia (table 3).

Dementia prediction accuracy. Discriminant analysis in which age, sex, and premorbid IQ and vascular risk factors were entered did not discriminate between dementia converters and nonconverters (Wilks lambda [*df* 9] = 0.865, $\chi^2 = 13.43$, $p = 0.144$). In contrast, discriminant analysis including the MRI variables found to be associated with progression to dementia in the previous multivariate Cox regression (i.e., change in MD-NPH, WMH, and premorbid IQ) and their MRI baseline values was significant (Wilks lambda [*df* 5] = 0.759, $\chi^2 = 24.64$; $p < 0.001$). It correctly classified 80.9% of patients with 80.0% sensitivity and 81.0% specificity and achieved an AUC of 0.849, corresponding to a C statistic of 0.849. After leave-one-out cross-validation, this model remained stable, with a sensitivity of 73.3% and specificity of 78.5%.

DISCUSSION In this longitudinal prospective study in symptomatic SVD, change in multimodal MRI measures over a 3-year period, during which little

change in cognition was detectable, predicted long-term cognitive decline and dementia. In particular, diffuse WM damage on DTI predicted decline in EF and progression to dementia. It was striking that while some patients had marked cognitive decline, others did not decline. This emphasizes the need for predictive tools to identify those who are likely to develop dementia both for individual risk prediction and to identify who may benefit from specific treatments. Our results suggest that MRI may be useful in risk prediction.

Previous cross-sectional studies using DTI have demonstrated abnormalities not only within WMH,²⁶ but also in NAWM,⁸ and have shown these DTI measures correlate with cognition more strongly than WMH volume.^{27,28} This finding, indicating that diffuse WM damage is associated with cognitive decline, has led to the hypothesis that disruption of WM tracks and secondary disconnection of complex cortical–subcortical networks causes cognitive impairment. However, cross-sectional studies demonstrate association, but cannot prove causality. Longitudinal studies provide stronger evidence that associations are causal. This study provides some of the first evidence that change in DTI measures correlates with subsequent cognitive decline in SVD, and therefore provides support for the hypothesis that

Table 3 Predictors of conversion to dementia in cerebral small vessel disease

	Univariate Cox regression			Multivariate Cox regression		
	Hazard ratio	95% CI	p Value	Hazard ratio	95% CI	p Value
Baseline age, y	1.020	0.97-1.07	0.443	—	—	—
Baseline IQ	0.975	0.94-1.01	0.124	0.958	0.93-0.99	0.017
Sex (male)	1.930	0.64-5.87	0.246	—	—	—
Vascular risk factors						
Diabetes	1.232	0.44-3.46	0.692	—	—	—
Current smoker	1.910	0.64-5.71	0.246	—	—	—
Ex-smoker	0.767	0.24-2.42	0.650	—	—	—
Mean diastolic BP	0.952	0.90-1.01	0.113	—	—	—
Mean systolic BP	1.020	0.99-1.05	0.162	—	—	—
Mean total cholesterol	0.738	0.48-1.13	0.165	—	—	—
Mean BMI	0.955	0.86-1.06	0.370	—	—	—
Annualized change in MRI measures						
WMH lesion load (log)	1.6×10^6	$0.17-1.6 \times 10^{11}$	0.088	2.5×10^6	$1.80-3.57 \times 10^{12}$	0.041
TCV	1.009	0.97-1.05	0.669	—	—	—
MD-NPH ($\times 10^3$)	0.004	$2.0 \times 10^{-5}-0.65$	0.034	0.0002	$3.7 \times 10^{-7}-0.12$	0.009
Incident lacunes	1.089	0.38-3.09	0.873	—	—	—
Incident CMB	2.312	0.09-6.00	0.085	—	—	—

Abbreviations: BMI = body mass index, in kg/m²; BP = blood pressure, in mm Hg; CMB = cerebral microbleeds; MD-NPH = normalized peak height of mean diffusivity histogram distribution, in mm²/s; TCV = total cerebral volume, in mL; WMH = white matter hyperintensity, in % of total cerebral volume log transformed.

Mean total cholesterol was measured in mmol/L.

diffuse WM damage on DTI causes cognitive impairment.

Using discriminant analysis, we showed that WM microstructure in addition to WMH lesion load and premorbid IQ had significant power to discriminate dementia converters from nonconverters with a C statistic of 0.849. This is a level of prediction that would be clinically useful and is, for example, higher than the 0.81 previously reported for an all-dementia model, which included MRI variables in addition to demographic, vascular risk factor, and cognitive variables.²⁹ Replication in further independent SVD test populations is needed.

Our results provide further support for the validity of MRI measures as surrogate markers in clinical trials evaluating new treatments for SVD. Currently there are few effective treatments for patients with SVD-related cognitive decline. A major obstacle to assessing new treatments is the lack of detectable longitudinal change in cognition over short time periods.^{3,7} This has led to the suggestion that MRI measures may be useful to assess new therapies.^{7,30} Using MRI markers could markedly reduce sample sizes required to detect treatment effects.⁷ However, before such a surrogate marker is adopted clinically, it is essential to show that change in the marker correlates with change in clinical endpoints. Our study provides some of the first data that this is indeed the case with change in MD-NPH, the DTI measure most sensitive to change,²⁰ correlating with eventual cognitive decline and progression to dementia.

Previous cross-sectional studies in SVD have shown that, in addition to WM damage imaged on DTI, lacunar infarcts^{31,32} and brain volume^{9,33} are also associated with cognitive impairment, while inconsistent associations have been shown for CMB.^{31,34,35} In this study, new lacunar infarcts were associated with decline in EF. Although 74 new lacunar infarcts were detected over 3 years of imaging follow-up, only 3 patients had symptomatic lacunar strokes in this period. Therefore, although the vast majority of new lacunar infarcts are apparently asymptomatic, they are associated with cognitive decline. It has been hypothesized that lacunar infarcts do so by causing previously mentioned disconnection.³² Support for this has been provided by cross-sectional data showing that network efficiency mediates the association of lacunar infarcts on cognitive impairment.³⁶ In contrast to previous cross-sectional data, we did not find any association between brain volume and cognitive decline or dementia despite a detectable decline in volume over time.

Previous studies have shown little or no cognitive change over shorter time periods in this patient group.⁴ An analysis of cognition at 3 years in the same SCANS study showed minimal detectable change,⁴

and in the large SPS3 trial in MRI-confirmed lacunar stroke no change was detected over a 2-year period either.³ The current study shows that with longer follow-up, change is detectable. The lack of cognitive change over shorter periods of time is likely to be a reflection of testing methodology (i.e., variability in test results and learning effects), as well as the slow rate of cognitive decline in some individuals.

In contrast to associations we found between DTI measures and EF, we found no association with decline in PS. This is perhaps surprising in light of the association between PS and MRI measures in previous cross-sectional studies.^{10,37} This may reflect the relatively large motor performance component in our PS measure leading to reduced specificity. Alternatively, the mechanisms underlying PS impairment in SVD might differ from those causing EF impairment. PS impairment has been shown to associate with global efficiency derived from DTI tractography networks,¹⁴ and may be a consequence of more diffuse network disruption. Decline in PS may thus be better described by alternative analysis methods such as network analysis.³⁶

The present study had a number of limitations. First, it suffered from moderate data loss during follow-up, although the dropout rate is comparable to longitudinal aging studies.³⁸ As reported previously, patients without complete follow-up tended to be older and more disabled,^{4,7} which may have led to an underestimation of MRI and cognitive progression rates. Second, all MRI data were acquired on a 1.5T scanner. Although the same scanner was used, which was not upgraded during the duration of the study, image data quality could be improved by higher field strengths and spatial resolution with isotropic voxel dimensions.³⁹ SVD represents a spectrum of disease from asymptomatic WMH in community populations through to patients with multiple lacunes and extensive WMH who present with vascular dementia.¹ This study investigated a population with moderate to severe symptomatic SVD who have a higher risk of progressing to dementia. In this specific patient group, we showed that a significant proportion progresses to dementia over 5 years. Our results now require replication in patients with less severe SVD, such as in community studies, in which WM DTI measures have been shown to correlate with cognition cross-sectionally.^{27,40}

AUTHOR CONTRIBUTIONS

Concept and design of study: E.A.Z., R.L.B., R.G.M., T.R.B., H.S.M. Data acquisition and analysis: E.A.Z., A.J.L., C.L., P.B., A.D.M. Manuscript preparation: E.A.Z., A.J.L., C.L., P.B., R.L.B., R.G.M., T.R.B., H.S.M.

ACKNOWLEDGMENT

The authors thank Dr. Lalit Kalra and Dr. Tony Rudd for help with recruitment.

STUDY FUNDING

Supported by Wellcome Trust grant (081589). Recruitment was supported by the English National Institute of Health Research (NIHR) Clinical Stroke Research Network. The Article Processing Charge was funded by the Wellcome Trust.

DISCLOSURE

E. Zeestraten reports no disclosures relevant to the manuscript. A. Lawrence is supported by a project grant from Alzheimer's Research UK (ARUK-EXT2015B-1). C. Lambert and P. Benjamin report no disclosures relevant to the manuscript. R. Brookes is supported by a British Heart Foundation Project Grant (PG/13/30/30005). A. Mackinnon, R. Morris, and T. Barrick report no disclosures relevant to the manuscript. H. Markus is supported by an NIHR Senior Investigator award and his work is supported by the Cambridge University Hospital Comprehensive NIHR Biomedical Research Unit. Go to Neurology.org for full disclosures.


Received September 29, 2016. Accepted in final form August 16, 2017.

REFERENCES

1. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. *Lancet Neurol* 2010;9:689–701.
2. DeBette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. *BMJ* 2010;341:c3666.
3. Pearce LA, McClure LA, Anderson DC, et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. *Lancet Neurol* 2014;13:1177–1185.
4. Lawrence AJ, Brookes RL, Zeestraten EA, Barrick TR, Morris RG, Markus HS. Pattern and rate of cognitive decline in cerebral small vessel disease: a prospective study. *PLoS One* 2015;10:e0135523.
5. Patel B, Markus HS. Magnetic resonance imaging in cerebral small vessel disease and its use as a surrogate disease marker. *Int J Stroke* 2011;6:47–59.
6. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol* 2013;12:822–838.
7. Benjamin P, Zeestraten EA, Lambert C, et al. Progression of MRI markers in cerebral small vessel disease: sample size considerations for clinical trials. *J Cereb Blood Flow Metab* 2016;36:228–240.
8. O'Sullivan M, Summers PE, Jones DK, Jarosz JM, Williams SCR, Markus HS. Normal-appearing white matter in ischemic leukoaraiosis: a diffusion tensor MRI study. *Neurology* 2001;57:2301–2310.
9. Nitkunan A, Lanfranconi S, Charlton RA, Barrick TR, Markus HS. Brain atrophy and cerebral small vessel disease: a prospective follow-up study. *Stroke* 2011;42:133–138.
10. Lawrence AJ, Patel B, Morris RG, et al. Mechanisms of cognitive impairment in cerebral small vessel disease: multimodal MRI results from the St George's Cognition and Neuroimaging in Stroke (SCANS) study. *PLoS One* 2013;8:e61014.
11. Carey CL, Kramer JH, Josephson SA, et al. Subcortical lacunes are associated with executive dysfunction in cognitively normal elderly. *Stroke* 2008;39:397–402.
12. Jokinen H, Lipsanen J, Schmidt R, et al. Brain atrophy accelerates cognitive decline in cerebral small vessel disease: the LADIS study. *Neurology* 2012;78:1785–1792.
13. O'Sullivan M, Jones DK, Summers PE, Morris RG, Williams SCR, Markus HS. Evidence for cortical “disconnection” as a mechanism of age-related cognitive decline. *Neurology* 2001;57:632–638.
14. Lawrence AJ, Chung A, Morris RG, Markus HS, Barrick TR. Structural network efficiency is associated with cognitive impairment in small vessel disease. *Neurology* 2014;44:1–24.
15. Bamford J, Sandercock P, Jones L, Warlow C. The natural history of lacunar infarction: the Oxfordshire Community Stroke Project. *Stroke* 1987;18:545–551.
16. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. *Am J Roentgenol* 1987;149:351–356.
17. Linn J, Halpin A, Demaerel P, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. *Neurology* 2010;74:1346–1350.
18. Lambert C, Benjamin P, Zeestraten EA, Lawrence AJ, Barrick TR, Markus HS. Longitudinal patterns of leukoaraiosis and brain atrophy in symptomatic small vessel disease. *Brain* 2016;139:1136–1151.
19. Cordonnier C, Potter GM, Jackson CA, et al. Improving interrater agreement about brain microbleeds: development of the brain observer microbleed scale (BOMBS). *Stroke* 2009;40:94–99.
20. Zeestraten EA, Benjamin P, Lambert C, et al. Application of diffusion tensor imaging parameters to detect change in longitudinal studies in cerebral small vessel disease. *PLoS One* 2016;11:e0147836.
21. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders, 5th ed (DSM-5)*. Washington, DC: American Psychiatric Association; 2013.
22. Tombaugh TN, McIntyre NJ. The Mini-Mental State Examination: a comprehensive review. *J Am Geriatr Soc* 1992;40:922–935.
23. Barberger-Gateau P, Commenger D, Gagnon M, Letenneur L, Sauvel C, Dartigues J-F. Instrumental Activities of Daily Living as a screening tool for cognitive impairment and dementia in elderly community dwellers. *J Am Geriatr Soc* 1992;40:1129–1134.
24. Rasbash J, Charlton C, Browne WJ, Healy M, Cameron B. *MLwiN Version 2.1. Centre for Multilevel Modelling*. Bristol: University of Bristol; 2009.
25. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiology* 1982;143:29–36.
26. Jones DK, Lythgoe D, Horsfield MA, Simmons A, Williams SCR, Markus HS. Characterization of white matter damage in ischemic leukoaraiosis with diffusion tensor MRI. *Stroke* 1999;30:393–397.
27. della Nave R, Foresti S, Pratesi A, et al. Whole-brain histogram and voxel-based analyses of diffusion tensor imaging in patients with leukoaraiosis: correlation with motor and cognitive impairment. *AJNR Am J Neuroradiol* 2007;28:1313–1319.
28. Nitkunan A, Barrick TR, Charlton RA, Clark CA, Markus HS. Multimodal MRI in cerebral small vessel disease: its relationship with cognition and sensitivity to change over time. *Stroke* 2008;39:1999–2005.
29. Barnes DE, Covinsky KE, Whitmer RA, Kuller LH, Lopez OL, Yaffe K. Predicting risk of dementia in older adults: the late-life dementia risk index. *Neurology* 2009;73:173–179.

30. Schmidt R, Seiler S, Loitfelder M. Longitudinal change of small-vessel disease-related brain abnormalities. *J Cereb Blood Flow Metab* 2016;36:1–8.
31. Viswanathan A, Gschwendtner A, Guichard J-P, et al. Lacunar lesions are independently associated with disability and cognitive impairment in CADASIL. *Neurology* 2007;69:172–179.
32. Benjamin P, Lawrence AJ, Lambert C, et al. Strategic lacunes and their relationship to cognitive impairment in cerebral small vessel disease. *Neuroimage Clin* 2014;4: 828–837.
33. Viswanathan A, Godin O, Jouvent E, et al. Impact of MRI markers in subcortical vascular dementia: a multimodal analysis in CADASIL. *Neurobiol Aging* 2010;31: 1629–1636.
34. Patel B, Lawrence AJ, Chung AW, et al. Cerebral microbleeds and cognition in patients with symptomatic small vessel disease. *Stroke* 2013;44:356–361.
35. Werring DJ, Frazer DW, Coward LJ, et al. Cognitive dysfunction in patients with cerebral microbleeds on T2*-weighted gradient-echo MRI. *Brain* 2004;127: 2265–2275.
36. Tuladhar AM, van Dijk E, Zwiers MP, et al. Structural network connectivity and cognition in cerebral small vessel disease. *Hum Brain Mapp* 2016;37:300–310.
37. Schmidt R, Ropele S, Ferro J, et al. Diffusion-weighted imaging and cognition in the leukoariosis and disability in the elderly study. *Stroke* 2010;41:402–408.
38. Glymour MM, Chêne G, Tzourio C, Dufouil C. Brain MRI markers and dropout in a longitudinal study of cognitive aging: the Three-City Dijon Study. *Neurology* 2012;79:1340–1348.
39. Vrenken H, Jenkinson M, Horsfield MA, et al. Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. *J Neurol* 2013;260:2458–2471.
40. Hannesdottir K, Nitkunan A, Charlton RA, Barrick TR, MacGregor GA, Markus HS. Cognitive impairment and white matter damage in hypertension: a pilot study. *Acta Neurol Scand* 2009;119:261–268.

This Week's *Neurology*[®] Podcast



Change in multimodal MRI markers predicts dementia risk in cerebral small vessel disease (see p. 1869)

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the October 31, 2017, issue of *Neurology*. In the first segment, Dr. Matthew Elliot talks with Dr. Hugh Markus about his paper on multimodal MRI markers and dementia risk in cerebral small vessel disease. In the second part of the podcast, Dr. Brian Eckerle focuses his interview with Dr. Charles Pollack on dabigatran reversal in patients with uncontrolled bleeding or receiving surgery.

Disclosures can be found at Neurology.org.

At Neurology.org, click on “RSS” in the Neurology Podcast box to listen to the most recent podcast and subscribe to the RSS feed.

CME Opportunity: Listen to this week's *Neurology* Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.

Get Connected. Stay Connected.

Connect with the American Academy of Neurology's popular social media channels to stay up-to-date on the latest news and breakthroughs in neurology, and network with peers and neurology thought leaders. Visit AAN.com/Connect.